Accumulating data supports that by only inhibiting the intrinsic coagulation pathway via FXI blockade provides a new efficacious antithrombotic approach with low bleeding risk.

RBD4059 is a first in class siRNA targeting Factor XI.

RBD4059 showed good effects in non-human primate and in mouse models (presented at ESC 2023).

For a Factor XI therapy RBD4059 is anticipated to provide high patient adherance to therapy, high potency and long durable effect with no need for monitoring and no specific antidote required.

RBD 4059 has demonstrated high potency/efficacy & duration against Factor XI inhibition with a large safety margin. As the first in class siRNA against Factor XI it is now in phase 1 clinical trials.

RBD4059 composition of matter IP until